NHS-muIL12

NHS-muIL12 is a **tumor-targeting immunocytokine** designed for preclinical studies in mice. It consists of murine interleukin-12 (IL-12) genetically fused to an antibody fragment (NHS76) that binds exposed DNA in necrotic regions of tumors. By delivering IL-12 directly to the tumor microenvironment, NHS-muIL12 activates both innate and adaptive immune responses, notably inducing IFN-γ production and robust activation and infiltration of cytotoxic CD8+ T cells and NK cells within tumors. It also mediates the maturation of dendritic cells (DCs), upregulates MHC class I expression, polarizes macrophages toward an M1 phenotype, and reduces populations of tumor-promoting myeloid-derived suppressor cells (MDSCs). Its heightened selectivity for necrotic tumor tissue helps minimize systemic toxicity compared to recombinant IL-12. NHS-muIL12 has been shown in preclinical models to synergize with immune checkpoint inhibitors (such as anti-PD-L1) and cancer vaccines to enhance anti-tumor efficacy and promote immunological memory. This drug is not for human use but serves as the murine analog for translational research leading to the clinical agent NHS-IL12[2][3][4].

Other names

NHS-muIL12NHS-muIL-12NHS-muIL 12NHS-IL12 (murine)murine NHS-IL12